New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
(WorldNews Health)

Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63 vs 2.98) and the annual rate of days hospitalized (4 vs 6.87) in a 52-week study2 Approximately 100,000 people in the United States, most of whom are of African descent, have sickle cell disease3 Approval comes approximately two months ahead of FDA`s priority review action date, allowing Adakveo to be available to patients more quickly Basel, November 15, 2019- Novartis announced today that the US Food and Drug Administration (FDA) approved Adakveo® (crizanlizumab), previously known as SEG101, to...